The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ACET | -36.92% | -95.02% | -45.08% | -96% |
| S&P | +13.19% | +87.83% | +13.42% | +99% |
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
These companies' share prices could rise in the short term, but their long-term opportunities are even better.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$1.60M | -0.5% |
| Market Cap | $67.45M | -43.2% |
| Market Cap / Employee | $0.44M | 0.0% |
| Employees | 152 | 6.3% |
| Net Income | -$26.86M | 11.9% |
| EBITDA | -$26.35M | 16.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $29.10M | -72.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $12.27M | -17.8% |
| Short Term Debt | $3.27M | -0.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -59.52% | -10.3% |
| Return On Invested Capital | -40.82% | -1.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$22.52M | -0.5% |
| Operating Free Cash Flow | -$22.31M | -1.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.37 | 0.33 | 0.31 | 0.51 | 0.20% |
| Price to Tangible Book Value | 0.37 | 0.33 | 0.31 | 0.51 | 0.20% |
| Enterprise Value to EBITDA | 2.46 | 2.32 | 1.76 | 0.52 | -68.93% |
| Return on Equity | -65.7% | -55.8% | -64.4% | -71.7% | 23.59% |
| Total Debt | $17.23M | $16.25M | $15.36M | $15.54M | -14.63% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
